Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder
Ruyun Liu,Ning Liu,Lin Ma,Yue Liu,Zhuo Huang,Xiaodong Peng,Chunlin Zhuang,Jianguo Niu,Jianqiang Yu,Juan Du
DOI: https://doi.org/10.1007/s40263-024-01123-x
2024-10-10
CNS Drugs
Abstract:Major depressive disorder (MDD) is a severe mental illness with a complex etiology. Currently, many medications employed in clinical treatment exhibit limitations such as delayed onset of action and a high incidence of adverse reactions. Therefore, there is a pressing need to develop antidepressants that exhibit enhanced efficacy and safety. The N -methyl- d -aspartate receptor (NMDAR), a distinctive glutamate-gated ion channel receptor, has been implicated in the onset and progression of depressive disorder, as evidenced by both preclinical and clinical research. The NMDAR antagonist, ketamine, exhibits rapid and sustained antidepressant effects, holding promise as a novel therapeutic approach for depressive disorder. However, its psychotomimetic impact and potential for addiction have restricted its widespread clinical application. Notably, over the past decade, studies have suggested that enhancing NMDAR functionality can produce antidepressant effects with improved safety, especially with the emergence of NMDAR-positive allosteric modulators (PAMs). We view this as a potential novel strategy for treating depression, forming the basis for the narrative review that follows.
pharmacology & pharmacy,psychiatry,clinical neurology